TrialThe journal of headache and pain2022

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.

Shengyuan Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.